Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- presença de fatores de risco
- ansiedade antecipatória e preocupação
- taquicardia
- hiperventilação
- sudorese
- rubor
- tensão muscular
Outros fatores diagnósticos
- processamento pós-evento
- vieses de atenção
- deficits de habilidades sociais
- choro, acessos de raiva ou "paralisia"
Fatores de risco
- comorbidade psiquiátrica (por exemplo, transtornos de ansiedade, humor e abuso de substâncias)
- genética
- fatores de temperamento
- estilo de criação
- transtorno psicológico
- estressores da vida
- fatores ambientais
Investigações diagnósticas
Investigações a serem consideradas
- glicose sanguínea
- hormônio estimulante da tireoide sérico
- análise toxicológica (urina e sangue)
Algoritmo de tratamento
Colaboradores
Autores
Associate Professor
Department of Psychiatry and Psychology
Mayo Clinic
Rochester
MN
Declarações
CNS declares that he has no competing interests.
Assistant Professor
Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
Seattle
WA
Declarações
JPV declares that he has no competing interests.
Associate Professor
Department of Psychological Sciences
Vanderbilt University
Nashville
TN
Declarações
BOO declares that he has no competing interests.
Director
Anxiety and Stress Reduction Center of Seattle
University of Washington
Seattle
WA
Declarações
SSW declares that she has no competing interests.
Revisores
Emeritus Professor
Medical Director
Anxiety Treatment and Research Centre
McMaster University and St Joseph’s Hospital
Hamilton
Canada
Declarações
RPS declares that he has no competing interests.
Professor
Department of Psychology
University of Arkansas
Fayetteville
AR
Declarações
JML declares that he has no competing interests.
Associate Professor
Institute of Living
Yale University
New Haven
CT
Declarações
DFT declares that he has no competing interests.
Professor of Psychiatry
University of Southampton
Southampton
UK
Declarações
DB has acted as a consultant for and held research grants from Cephalon, Eli Lilly, GSK, Lundbeck, Organon, Pfizer, Pharmacia, Roche, and Wyeth and has also acted as a consultant to Asahi, AstraZeneca, Grunenthal, Pierre Fabre, Servier, Sumitomo, and Wyeth. He has accepted paid speaking engagements in industry-supported satellite symposia and is co-author of the BAP evidence-based guidelines on the treatment of anxiety disorders. He is also a Medical Patron of Anxiety UK.
O uso deste conteúdo está sujeito ao nosso aviso legal